Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07252830

Identification of Asymptomatic Patients at Very High Cardiovascular Risk: Contribution of a Strategy Based on Carotid and Coronary Explorations, Compared to Simple Risk Calculation Using the European "SCORE 2" Algorithm. (IDEA-CVR)

To prevent myocardial infarction ( MI), coronary atheroma development by LDL-cholesterol deposition in the arterial wall is the basis. Since atheromatous plaques develop slowly before becoming symptomatic, their early detection in asymptomatic patients and the implementation of an effective strategy to prevent their progression constitute the most promising primary prevention strategy. In younger subjects, the main modifiable pro-atheromatous factors are smoking and an excessively high LDL-C level, partly genetically predetermined, but also favored by a diet too rich in saturated fats and a lack of physical activity. In the French national MI registry, the average age of patients is 62 years (Arch Cardiovasc Dis 2021 Oct;114(10):647-655). Half of MIs therefore occur at working age due to rupture of atheromatous plaques, which had developed during the months/years preceding the acute event.

According to the latest recommendations of the European Society of Cardiology (ESC) on CV prevention published in August 2021, the visualization of coronary or carotid atheromatous plaques justifies considering the patient as having atherosclerotic cardiovascular disease (ASCVD), and automatically places them in the "very high CV risk" category, with an LDL-cholesterol target of <0.55 g/L. However, these recommendations do not clearly define the criteria justifying the use of imaging in asymptomatic patients.

In current practice, CV risk stratification for asymptomatic patients with no prior CV disease is currently based on risk calculation using the European "SCORE 2" algorithm, available online. It allows the calculation of the absolute risk in % of occurrence of a fatal or non-fatal CV event (myocardial infarction, stroke) over 10 years.

The main objective of this study is to describe patients reclassified as "very high CV risk" following the detection of atheroma plaques formed in relation to their risk level estimated by SCORE2.

Recruiting

Interested in participating?

Request Info

Key information

Age range

40 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Polyclinqiue de Poitiers

Poitiers, 86000, France

Location status: Recruiting

Location contact

Barnabas Gellen, Dr

CONTACT

+33 5 49 61 71 99

About this study

It is a national, single-center, retrospective and prospective study on the collection of routine care data.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age > 40 years and < 80 years referred to general cardiology consultation
  • LDL-C level > 1.6 g/L, or LDL-C level > 1.3 g/L with at least one associated major cardiovascular (CV) risk factor (RCF) (smoking, hypertension, diabetes).
  • Coronary artery reserve assessment and EDTSA performed in a day hospital

Exclusion criteria

  • Known or suspected carotid atherosclerotic disease
  • Significant ischemic heart disease known or suspected at the time of the initial consultation
  • Protected adult patient (patient under guardianship, curatorship, or other legal protection, deprived of liberty by judicial or administrative decision)
  • Opposition expressed by the patient to the use of their health data.
  • Patient may have limited understanding of the information sheet

Treatment and study plan

SCORE2

Other

the European algorithm "SCORE 2", available online (figure 1). It allows the calculation of the absolute risk in % of occurrence of a fatal or non-fatal CV event (myocardial infarction, stroke) over 10 years.

Primary outcomes

  1. Very high risk cardiovascular (yes/no)

    Time frame: 12 months

    Patients reclassified as "very high CV risk" (Yes/No) compared to the risk level estimated by SCORE2.

    SCORE2 is determined by an online calculator from the European Society of Cardiology (ESC).

Study contacts

Contact information is provided by the study sponsor or research team.

Aurelia Cassany, Dr

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Elsan

Other

Collaborators

  • Polyclinique Poitiers

Registry information

Official study title

Identification of Asymptomatic Patients at Very High Cardiovascular Risk: Contribution of a Strategy Based on Carotid and Coronary Explorations, Compared to Simple Risk Calculation Using the European "SCORE 2" Algorithm.

Acronym: IDEA-CVR

Important dates

Study start
2021
Primary completion
2025
Study completion
2026
First posted
Nov 28, 2025
Registry last updated
Nov 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.